LONDON--(BUSINESS WIRE)--According to the latest report published by Technavio, the central nervous system disorders therapeutics market size is poised to grow by USD 23.16 billion during 2020-2024, progressing at a CAGR of over 4% during the forecast period.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment facing direct and indirect COVID-19 impact.
To learn more about the global trends impacting the future of market research, download a free sample now
Market Competitive Analysis:
The market is fragmented due to the presence of central nervous system disorders therapeutics manufacturing companies. AstraZeneca Plc, Boehringer Ingelheim International GmbH, and Eli Lilly and Co. are some of the major market participants.
- Although the increasing prevalence of CNS disorders will offer immense growth opportunities, the high failure rates of late-stage products in clinical trials will challenge the growth of the market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their position in the slow-growing segments.
- To help clients improve their market position, this central nervous system disorders therapeutics market forecast report provides a detailed analysis of the market leaders. It offers information on the competencies and capacities of these companies.
- The report also covers details on the market's competitive landscape and offers information on the products offered by various companies. Moreover, this central nervous system disorders therapeutics market analysis report also provides information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of their future growth opportunities.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
View market snapshot before purchasing
This report provides information on the production, sustainability, and prospects of several leading companies, including:
- AstraZeneca Plc
- Boehringer Ingelheim International GmbH
- Eli Lilly and Co.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Johnson & Johnson
- Merck & Co. Inc.
- Novartis AG
- Otsuka Holdings Co. Ltd.
- Pfizer Inc.
Global Central Nervous System Disorders Therapeutics Market: COVID-19 Impact Analysis
Market Impact:
As the business impact of COVID-19 spreads, the global central nervous system disorders therapeutics market 2020-2024 market is expected to have superior growth.
Industry Impact:
The healthcare industry is expected to have a positive impact due to the spread of the COVID-19 virus. The healthcare market will have a direct impact due to the spread. Even if the spread of the virus is contained, we expect that it may take more than two quarters (six months) to reach a normal state of economic activity.
Register for a free trial today and gain instant access to 17,000+ market research reports.
Technavio's SUBSCRIPTION platform
Key Highlights of the Report for 2020-2024:
- CAGR of the market during the forecast period 2019-2024
- Detailed information on factors that will drive central nervous system disorders therapeutics market growth during the next five years
- Precise estimation of the central nervous system disorders therapeutics market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in market dynamics
- The growth of the central nervous system disorders therapeutics market industry across North America, Europe, Asia, and ROW
- A thorough analysis of the market's competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of central nervous system disorders therapeutics market vendors
Download a free sample of report with COVID-19 crisis and recovery analysis.
Executive Summary
Market Landscape
- Market ecosystem
- Market characteristics
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2019
- Market outlook: Forecast for 2019 - 2024
Five Forces Analysis
- Five forces summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Type
- Market segments
- Comparison by Type
- Depression drugs - Market size and forecast 2019-2024
- Multiple sclerosis drugs - Market size and forecast 2019-2024
- Schizophrenia drugs - Market size and forecast 2019-2024
- Bipolar disorder therapeutics - Market size and forecast 2019-2024
- Alzheimer disease drugs - Market size and forecast 2019-2024
- Epilepsy drugs - Market size and forecast 2019-2024
- Parkinson disease drugs - Market size and forecast 2019-2024
- Others - Market size and forecast 2019-2024
- Market opportunity by Type
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2019-2024
- Europe - Market size and forecast 2019-2024
- Asia - Market size and forecast 2019-2024
- ROW - Market size and forecast 2019-2024
- Key leading countries
- Market opportunity by geography
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Competitive scenario
- Vendor landscape
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- AstraZeneca Plc
- Boehringer Ingelheim International GmbH
- Eli Lilly and Co.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Johnson & Johnson
- Merck & Co. Inc.
- Novartis AG
- Otsuka Holdings Co. Ltd.
- Pfizer Inc.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
